<DOC>
	<DOCNO>NCT00963196</DOCNO>
	<brief_summary>This study randomize controlled trial set outpatient clinic , involve patient major depressive disorder , treat antidepressant therapy , individually agree upon subject physician . Patients randomize receive either placebo fish oil capsule contain eicosapentaenoic acid ( EHA ) docosahexaenoic acid ( DHA ) addition antidepressant medication . Subjects complete brief dietary exercise habit survey begin trial take account lifestyle factor may significant symptom resolution . Their progress monitor period twelve week , standardize rating scale complete subject treat physician . At end study , score compare group look difference time degree symptom improvement analyze whether improvement occur faster group receive essential fatty acid ( EFAs ) one receive placebo . The primary hypothesis supplementation antidepressant therapy omega-3 fatty acid decrease lag period start therapy time clinically significant symptom improvement . A secondary hypothesis result study consistent numerous previous study show improvement symptom control major depressive disorder antidepressant supplement omega-3 fatty acid .</brief_summary>
	<brief_title>Study Supplementation Antidepressants With Fish Oil Improve Time Clinical Response</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Diagnosis Major Depressive Disorder . Allowed comorbidities : Dysthymia , Anxiety Disorders . 18 year old old . Males + Females . Englishspeaking . Women reproductive age must adequate birth control , either oral contraceptive use condom barrier method spermicidal agent . Subjects may undergo psychotherapy , must maintain current psychotherapy status . Must start therapy already therapy . If therapy , must receive least 6 session prior enter study . Subjects may continue take herbal supplement study , may start new herbal supplement study . 2 fail trial antidepressant ( adequate dose duration , document ) . Substance dependence past 6 month . Current substance use abuse ( MJ , benzodiazepine , narcotic ) . If BZD use , patient must taper wait 1 month include trial . Psychosis . Bipolar Affective Disorder Type I , II NOS . Pregnancy ( current plan ) . Unstable medical illness ( pt stable least 3 month , may exclude per investigator discretion ) . Dementia . Mental retardation . Traumatic Brain Injury . History Stroke . History seizure disorder . Electroconvulsive therapy within past 6 month . If , investigator 's discretion , suspect subject likely comply study protocol . Imminent risk suicide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>